Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Neuroendocrine tumors (NETs) are rare cancers requiring systemic therapy for advanced, unresectable cases.
• Systemic therapy is an established treatment for NETs, supported by some evidence, but high-quality clinical trials are limited.
• Research into NET molecular biology is advancing, paving the way for novel, mechanism-driven treatments.

Purpose of the Study:

• To review the current oncology literature on systemic therapy for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
• To elucidate the role, benefits, and limitations of systemic therapy in managing advanced, unresectable GEP-NETs.
• To discuss the rationale behind emerging targeted therapies informed by NET molecular biology.

Main Methods:

• Comprehensive literature search of oncology databases.
• Systematic review and synthesis of evidence on systemic therapies for GEP-NETs.
• Analysis of molecular targets and clinical trial data for novel therapies.

Main Results:

• Systemic therapy offers a treatment option for advanced NETs with an existing evidence base.
• Challenges in rare cancer research limit the number of well-designed clinical trials.
• New targeted therapies, driven by understanding NET molecular biology, show promise.

Conclusions:

• Systemic therapy plays a crucial role in managing advanced GEP-NETs.
• Further research is needed to optimize systemic treatment strategies and develop novel therapies.
• Understanding the molecular underpinnings of NETs is key to advancing targeted treatment options.